RDHL - RedHill Biopharma Ltd. Total Debt to Capital

Public company logo of RedHill Biopharma Ltd (RDHL)

RedHill Biopharma develops innovative therapies for digestive organs and infectious diseases in the US and Israel. This daily price chart illustrates a total debt-to-equity ratio of 0.00. The firm's financial success relies on the sales of Movantik and Talicia, as well as the progress of new oncology developments. The brand's high medical authority confirms its status as a reliable developer of effective pharmaceuticals.

RDHL: RedHill Total Debt to Capital 07/04/2022 - 11/01/2026

Analytical breakdowns for RedHill Biopharma

- price and consensus price forecast:
Price Chart RedHill Biopharma Ltd|RDHL - Forecast Levels Chart
- market capitalization statistics:
Market Capitalization RedHill Biopharma|RDHL - Value Adjusted for Debt and Cash
- book capitalization indicators:
Book Value per Share RedHill Biopharma|RDHL - Book Capitalization|Market Value to Book Value Ratio redhillbio.com|RDHL - Aggregate Asset Value
- company total debt and liquidity indicators:
Debt to Equity RedHill Biopharma|RDHL - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital RedHill Biopharma Ltd|RDHL - Company Aggregate Debts|Debt to Book Value RedHill Biopharma|RDHL - Company Long-Term Loans and Borrowings|Company Short-Term Debts RedHill Biopharma|Quick Ratio redhillbio.com
- earnings and valuation multiples information:
RDHL - Net Financial Result
Basic company analysis:RedHill Biopharma
Core merchandise of RedHill Biopharma Ltd.

For the Israel-based biotech sector, RedHill Biopharma (RDHL) finds the balance between debt and equity critical, particularly amid regional instability. Analyzing the company's financial leverage dynamics, we see the value of 0.00, which reflects the share of total liabilities within the capital structure, allowing investors to assess business resilience and the risk of default on debt service.

Competitor analysis for RedHill Biopharma

Debt to Equity Phathom Pharmaceuticals, Inc.|Terns Pharma - Aggregate Debt to Equity|Total Debt to Capital IRWD|CURX (curanexpharma.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital IMRN (Immuron)|Total Debt to Capital evokepharma.com EVOK|ENTO - Debt to Equity|All Debt to Shareholders' Equity Ratio PALI (Palisade Bio Inc.)|Jaguar Animal Health (JAGX) - Debt to Equity|Total Debt to Equity Ratio Biora Therapeutics, Inc|MORF (Morphic Holding, Inc.) - Total Debt to Capital